Dr. Robert Malone — a member of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices ...

Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...

At its root, public health is a matter of individual, personal responsibility for a community’s well-being and for the safety ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine - which designs nanotechnology-based platforms for clinical translation across specialties - developed a ...

Melanoma, known for its aggressiveness and high mutational burden, presents itself as a prime candidate for neoantigen-targeted immunotherapies. Although ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer ...

Moderna (MRNA) stock hits a 52-week high to extend its YTD rally following back-to-back years of declines. Read more here.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...